{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:24:14Z","timestamp":1791473054340,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012513","name":"Coins for Alzheimer's Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022504","name":"Dane G. Hansen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013356","name":"Cold Spring Harbor Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA53840"],"award-info":[{"award-number":["R01CA53840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA45508"],"award-info":[{"award-number":["CA45508"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jbc.2026.113178","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:20:48Z","timestamp":1779319248000},"page":"113178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B"],"prefix":"10.1016","volume":"302","author":[{"given":"Imanol","family":"Zubiete-Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-6444","authenticated-orcid":false,"given":"Steven R.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-2548","authenticated-orcid":false,"given":"Raditya","family":"Utama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-1538","authenticated-orcid":false,"given":"Nicholas K.","family":"Tonks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113178_bib1","first-page":"2095","article-title":"Rett and Rett-related disorders: common mechanisms for shared symptoms?","volume":"248","author":"D\u2019Mello","year":"2023","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.jbc.2026.113178_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-cpg-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1086\/426460","article-title":"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5\/STK9) gene are associated with severe neurodevelopmental retardation","volume":"75","author":"Tao","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/426462","article-title":"Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation","volume":"75","author":"Weaving","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib5","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.3390\/ijms20174176","article-title":"FOXG1-Related syndrome: from clinical to molecular genetics and pathogenic mechanisms","volume":"20","author":"Wong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front Neurosci."},{"key":"10.1016\/j.jbc.2026.113178_bib7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/ijms23020954","article-title":"Paving therapeutic avenues for FOXG1 syndrome: untangling genotypes and phenotypes from a molecular perspective","volume":"23","author":"Akol","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib8","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1007\/s13311-022-01295-8","article-title":"Expression of a secretable, cell-penetrating CDKL5 protein enhances the efficacy of gene therapy for CDKL5 deficiency disorder","volume":"19","author":"Medici","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jbc.2026.113178_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00727","article-title":"Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency","author":"Medici","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jbc.2026.113178_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41439-024-00296-7","article-title":"A case of CDKL5 deficiency disorder with a novel intragenic multi-exonic duplication","volume":"11","author":"Akiba","year":"2024","journal-title":"Hum. Genome"},{"key":"10.1016\/j.jbc.2026.113178_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/444549","article-title":"Duplication of the MECP2 Region is a frequent cause of severe mental retardation and progressive neurological symptoms in males","volume":"77","author":"Van Esch","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib12","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.3390\/ijms26146626","article-title":"Adult-Onset deletion of CDKL5 in forebrain glutamatergic neurons impairs synaptic integrity and behavior in mice","volume":"26","author":"Mottolese","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib13","article-title":"Excitation and inhibition imbalance in Rett Syndrome","volume":"16","author":"Li","year":"2022","journal-title":"Front Neurosci."},{"key":"10.1016\/j.jbc.2026.113178_bib14","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1172\/JCI80323","article-title":"PTP1B inhibition suggests a therapeutic strategy for Rett syndrome","volume":"125","author":"Krishnan","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbc.2026.113178_bib15","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/cdd.2016.36","article-title":"Metabolic reprogramming during neuronal differentiation","volume":"23","author":"Agostini","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbc.2026.113178_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113709","article-title":"Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders","volume":"155","author":"Olloquequi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jbc.2026.113178_bib17","doi-asserted-by":"crossref","first-page":"31682","DOI":"10.1074\/jbc.M114.603621","article-title":"Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor Kinase B (TrkB) signaling","volume":"289","author":"Ozek","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113178_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jbc.2026.113178_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","article-title":"CDKL5 deficiency disorder: clinical features, diagnosis, and management","volume":"21","author":"Leonard","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib20","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.3390\/ijms20205098","article-title":"Rett Syndrome and CDKL5 deficiency disorder: from bench to Clinic","volume":"20","author":"Kadam","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.seizure.2025.08.002","article-title":"Antiseizure medications in CDKL5 encephalopathy- systematic review","volume":"131","author":"Kalinowska-Doman","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.jbc.2026.113178_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pediatric16010002","article-title":"Current overview of CDKL-5 deficiency disorder treatment","volume":"16","author":"Dell\u2019Isola","year":"2024","journal-title":"Pediatr. Rep."},{"key":"10.1016\/j.jbc.2026.113178_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107669","article-title":"Ganaxolone in epilepsy: insights into a neurosteroid-based therapy","volume":"218","author":"Dell\u2019Isola","year":"2025","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jbc.2026.113178_bib24","doi-asserted-by":"crossref","DOI":"10.15190\/d.2025.7","article-title":"Novel medication ganaxolone for seizure disorders","volume":"13","author":"Chowdhury","year":"2025","journal-title":"Discoveries (Craiova)"},{"key":"10.1016\/j.jbc.2026.113178_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40272-024-00670-6","article-title":"Ganaxolone: a review in epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder","volume":"27","author":"Hoy","year":"2025","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.jbc.2026.113178_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.17826","article-title":"Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up","volume":"65","author":"Olson","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.jbc.2026.113178_bib27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3\u03b1-Hydroxy-3\u03b2-methyl-5\u03b1-pregnan-20-one), a selective, High-Affinity, steroid modulator of the \u03b3-Aminobutyric AcidA receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbc.2026.113178_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fendo.2020.00417","article-title":"Anti-apoptotic actions of allopregnanolone and ganaxolone mediated through membrane progesterone receptors (PAQRs) in neuronal cells","volume":"11","author":"Thomas","year":"2020","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jbc.2026.113178_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nchembio.1528","article-title":"Targeting the disordered C terminus of PTP1B with an allosteric inhibitor","volume":"10","author":"Krishnan","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2026.113178_bib30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1074\/jbc.C117.819110","article-title":"A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models","volume":"293","author":"Krishnan","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113178_bib31","doi-asserted-by":"crossref","DOI":"10.3791\/53193","article-title":"Differentiation of the SH-SY5Y human neuroblastoma cell line","author":"Shipley","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jbc.2026.113178_bib32","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1093\/hmg\/ddi391","article-title":"CDKL5\/Stk9 kinase inactivation is associated with neuronal developmental disorders","volume":"14","author":"Lin","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1042\/BST20220791","article-title":"CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development","volume":"50","author":"Van Bergen","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jbc.2026.113178_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.celrep.2017.12.083","article-title":"CDKL family kinases have evolved distinct structural features and ciliary function","volume":"22","author":"Canning","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2026.113178_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nbd.2014.06.006","article-title":"Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT\/GSK-3\u03b2 signaling","volume":"70","author":"Fuchs","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jbc.2026.113178_bib36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/375538","article-title":"Disruption of the serine\/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation","volume":"72","author":"Kalscheuer","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ejhg.2012.156","article-title":"The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy","volume":"21","author":"Fehr","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","article-title":"Cyclin-Dependent kinase-like 5 deficiency disorder: clinical review","volume":"97","author":"Olson","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143655","article-title":"Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder-related deficits","volume":"131","author":"Terzic","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbc.2026.113178_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1352\/1944-7558-129.2.101","article-title":"CDKL5 deficiency disorder: some lessons learned 20 years after the first description","volume":"129","author":"Pestana Knight","year":"2024","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.jbc.2026.113178_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110504","article-title":"Exploring neurodevelopment in CDKL5 deficiency disorder: current insights and future directions","volume":"171","author":"Dell\u2019Isola","year":"2025","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jbc.2026.113178_bib42","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.ymthe.2024.07.012","article-title":"Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder","volume":"32","author":"Voronin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbc.2026.113178_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11689-021-09384-z","article-title":"Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder","volume":"13","author":"Olson","year":"2021","journal-title":"J. Neurodev Disord."},{"key":"10.1016\/j.jbc.2026.113178_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/01926230701226575","article-title":"Food and drug administration, Center for drug evaluation and research","volume":"35","author":"Jacobs","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jbc.2026.113178_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0920-1211(00)00170-4","article-title":"Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial","volume":"42","author":"Kerrigan","year":"2000","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jbc.2026.113178_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/15357597221125238","article-title":"Ganaxolone: a new treatment for CDKL5 deficiency disorder","volume":"22","author":"Vossler","year":"2022","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.jbc.2026.113178_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14656566.2024.2342413","article-title":"A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy","volume":"25","author":"Khan","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jbc.2026.113178_bib49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejpn.2024.06.005","article-title":"Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial","volume":"51","author":"Downs","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091613","article-title":"Mapping pathological phenotypes in a mouse model of CDKL5 disorder","volume":"9","author":"Amendola","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jbc.2026.113178_bib51","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1093\/hmg\/ddx279","article-title":"Mice lacking cyclin-dependent kinase-like 5 manifest autistic and ADHD-like behaviors","volume":"26","author":"Jhang","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2026.113178_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196587","article-title":"Comprehensive behavioral analysis of the Cdkl5 knockout mice revealed significant enhancement in anxiety- and fear-related behaviors and impairment in both acquisition and long-term retention of spatial reference memory","volume":"13","author":"Okuda","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113178_bib53","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/s41467-019-10689-w","article-title":"Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113178_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106146","article-title":"Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder","volume":"182","author":"Tassinari","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jbc.2026.113178_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113388","article-title":"Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms","volume":"332","author":"Mulcahey","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105176","article-title":"X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder","volume":"148","author":"Terzic","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jbc.2026.113178_bib57","article-title":"Deficiency of cyclin-dependent Kinase-like 5 causes spontaneous epileptic seizures in neonatal mice","author":"Liao","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2026.113178_bib58","article-title":"Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases","author":"Tiganis","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1016\/j.jbc.2026.113178_bib59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/iub.2716","article-title":"Protein Tyrosine Phosphatases: mighty oaks from little acorns grow","volume":"75","author":"Tonks","year":"2023","journal-title":"IUBMB Life."},{"key":"10.1016\/j.jbc.2026.113178_bib60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.biopsych.2015.08.028","article-title":"Dendritic spine instability in a mouse model of CDKL5 disorder is rescued by insulin-like growth factor 1","volume":"80","author":"Della Sala","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jbc.2026.113178_bib61","doi-asserted-by":"crossref","first-page":"24923","DOI":"10.1074\/jbc.M113.482737","article-title":"Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth Factor-1 receptor and kinase BRK\/PTK6 in ovarian cancer cells","volume":"288","author":"Fan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113178_bib62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fncel.2019.00169","article-title":"Functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are rescued by a TrkB agonist","volume":"13","author":"Ren","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.jbc.2026.113178_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12974-021-02204-0","article-title":"Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder","volume":"18","author":"Galvani","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jbc.2026.113178_bib64","doi-asserted-by":"crossref","first-page":"8719","DOI":"10.3390\/ijms23158719","article-title":"Luteolin treatment ameliorates brain development and behavioral performance in a mouse model of CDKL5 deficiency disorder","volume":"23","author":"Tassinari","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12974-016-0545-3","article-title":"A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation","volume":"13","author":"Song","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jbc.2026.113178_bib66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2521944123","article-title":"PTP1B inhibition promotes microglial phagocytosis in alzheimer\u2019s disease models by enhancing Syk Signaling","volume":"123","author":"Cen","year":"2026","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jbc.2026.113178_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.592514","article-title":"Metabolic control of epilepsy: a promising therapeutic target for epilepsy","volume":"11","author":"Fei","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.jbc.2026.113178_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2019.02.028","article-title":"Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy","volume":"511","author":"Wen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2026.113178_bib69","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2020.00136","article-title":"The glucagon-like Peptide-1 analogue liraglutide reduces seizures susceptibility, cognition dysfunction and neuronal apoptosis in a mouse model of Dravet Syndrome","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.jbc.2026.113178_bib70","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbi.2024.02.008","article-title":"Overexpression of forebrain PTP1B leads to synaptic and cognitive impairments in obesity","volume":"117","author":"Ge","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jbc.2026.113178_bib71","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/s12035-020-01884-8","article-title":"Increased DNA damage and apoptosis in CDKL5-Deficient neurons","volume":"57","author":"Loi","year":"2020","journal-title":"Mol. Neurobiol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826020508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826020508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:32:31Z","timestamp":1786145551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826020508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0021925826020508"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113178","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.10.31.685887","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113178"}}